MALT1 Antibody

MALT1 was initially identified as a novel gene that was recurrently rearranged in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphomas along with the apoptosis inhibitor protein c-IAP2 (1). MALT1, along with the proteins CARMA1 and Bcl10 form an NF-kappaB-activating complex, termed the CBM signalsome, that acts downstream of lymphocyte antigen receptors as well as many other non-lymphoid cell-surface receptors that play a role in multiple cellular functions (2,3). MALT1 has proteolytic activity, and this activity is critical for full NF-kappaB response in T cell activation (4).